Satellos Bioscience Inc. (MSLE)
NASDAQ: MSLE · Real-Time Price · USD
6.63
-0.21 (-3.00%)
At close: Nov 13, 2026, 4:00 PM EST
6.70
+0.08 (1.13%)
After-hours: Nov 13, 2026, 7:30 PM EST
Satellos Bioscience Employees
As of December 31, 2025, Satellos Bioscience had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,902,714
Market Cap
141.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2024 | 17 | 1 | 6.25% | 14 | 3 |
| Dec 31, 2023 | 16 | - | - | 4 | 12 |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Adagene | 128 |
| Innate Pharma | 120 |
| Armata Pharmaceuticals | 61 |
| ALX Oncology Holdings | 48 |
| OnKure Therapeutics | 45 |
| Zura Bio | 40 |
| Compass Therapeutics | 39 |
MSLE News
- 1 day ago - Satellos reports Q3 EPS (53c), consensus (63c) - TheFly
- 1 day ago - Satellos Bioscience Earnings release: Q3 2026 - Filings
- 1 day ago - Satellos Bioscience Report: Q3 2026 - Filings
- 1 day ago - Satellos Bioscience MD&A: Q3 2026 - Filings
- 1 day ago - Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress - GlobeNewsWire
- 4 days ago - Satellos Bioscience Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results - MarketBeat
- 7 days ago - Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027 - Nasdaq